Orphan Drugs- development trends and strategies

The growth of pharma industries has slowed in recent years because of various reasons such as patent expiries, generic competition, drying pipelines, and increasingly stringent regulatory guidelines. Many blockbuster drugs will lose their exclusivity in next 5 years. Therefore, the current economic situation plus the huge generic competition shifted the focus of pharmaceutical companies from the essential medicines to the new business model — niche busters, also called orphan drugs.

  • Cost of drug development
  • Evidence-based policy making & commissioning
  • Orphan drug status- Various Probabilities
  • Challenges in assessing clinical relevance and cost effectiveness
  • Developments in Regulating Orphan Drug Approval

Related Conference of Orphan Drugs- development trends and strategies

August 21-23, 2017

3rd Annual Congress on Infectious Diseases

San Francisco, California, USA
September 7-9, 2017

6thEuro-Global Conference on Infectious Diseases

Paris, France
September 13-14, 2017

6th Annual Bacteriology and Parasitology Meeting

Singapore
October 30-November 1, 2017

3rd Annual Congress on Rare Diseases and Orphan Drugs


(10 Plenary Forums - 1 Event)
San Antonio, Texas, USA
December 07-08, 2017

EuroSciCon Conference on STD-AIDS

Rome, Italy
March 1-2, 2018

5th International congress on Infectious Diseases

Berlin, Germany
June 18-19, 2018

EuroSciCon Conference on Bacteriology

Paris, France

Orphan Drugs- development trends and strategies Conference Speakers

Recommended Sessions

Related Journals

Are you interested in